| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 36975 | Trends in Biotechnology | 2015 | 4 Pages |
Abstract
Only a few years ago pharmaceutical companies were excited about the potential of RNA interference (RNAi). Now, financial volatility and subsequent dissolutions of in-house facilities by pharmaceutical companies have had media channels pronouncing that RNAi therapeutics are dead. However, advances in nanomedicine may now help the vast potential of RNAi therapeutics to be fulfilled.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
João Conde, Natalie Artzi,